Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines

 
• By Mandy Jackson

Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.

Financial Report
Otezla will boost Amgen's 2020 sales as net price declines hit other drugs • Source: Shutterstock

More from Earnings

More from Business